Head-to-head · WeighScore
ClickSlim vs Zealthy
The verdict
ClickSlim takes it — 49.9/100 to 46.7/100.
ClickSlim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Wyoming-registered telehealth selling compounded tirzepatide and NAD+ on introductory rates that step up after the first month, with no published state list.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | ClickSlim | Zealthy |
|---|---|---|
| WeighScore | 49.9/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #491 | #496 |
| Semaglutide | Not disclosed | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $349/mo (compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #491 · C
Strengths
- Both the introductory and the ongoing price are published, so the step-up is visible before you buy
- States plainly that it is not a pharmacy or a drug manufacturer and that medication is dispensed by a licensed third party
- Text support line published with stated hours
- LegitScript certification verified against the issued seal, not just the badge
Where it loses points
- Its own NAD+ product card is labelled CONTAINS TIRZEPATIDE, which contradicts the product it is selling
- No state list is published; the site says only that services are available in most States
- Prices are among the highest in the category, at $349 ongoing for tirzepatide
- Registered at a Sheridan, Wyoming suite address commonly used as a mail-forwarding and registered-agent address
- Terms set arbitration in San Diego under California law while the company address is in Wyoming
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.